Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Glaucoma
FollowWhat is new in Glaucoma research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- Bimatoprost Implant SystemPhase 3 · NCT07218796 · NCT07218783
- bimatoprost ophthalmic solution 0.01% (Lumigan®)Phase 3 · NCT07661329
- Bimatoprost ophthalmic solution 0.01% YSBPPhase 3 · NCT07661329
- Citicoline eye drops 2%Phase 3 · NCT05710198
- Commercial IOLPhase 3 · NCT07218796 · NCT07218783
- COSOPT®Phase 3 · NCT07617532
- DE-117B Eye DropsPhase 3 · NCT06666855
- Gen 2 Travoprost Intracameral ImplantPhase 3 · NCT07075718 · NCT07495852
- HUC3-637Phase 3 · NCT07335211
- HUC3-637-RPhase 3 · NCT07335211
- LatanoprostPhase 3 · NCT06666855
- Low Energy SLTPhase 3 · NCT04967989
- Matching placeboPhase 3 · NCT05405868
- Mitomycin cPhase 3 · NCT06680245
- NicotinomidePhase 3 · NCT05405868
- OfloxacinPhase 3 · NCT03933631
- PilocarpinePhase 3 · NCT03933631
- PrednisolonePhase 3 · NCT03933631
- Product DNN.31.19.026Phase 3 · NCT07617532
- Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Phase 3 · NCT05401357
- SpyGlass IOLPhase 3 · NCT07218796 · NCT06120842 · NCT07218783
- Standard Energy SLTPhase 3 · NCT04967989
- Test - Bimatoprost 0.01% Ophthalmic SolutionPhase 3 · NCT05401357
- TFC-003Phase 3 · NCT07662759
- TFC-003-R1Phase 3 · NCT07662759
- TFC-003-R2+TFC-003-R3Phase 3 · NCT07662759
- Timolol eye drops 0.5%Phase 3 · NCT07036510 · NCT07075718 · NCT07495852
- Timolol Maleate Ophthalmic Solution, 0.5%Phase 3 · NCT07218796 · NCT06120842 · NCT07218783
- XEN63 Glaucoma Treatment SystemPhase 3 · NCT06822738
- Dietary supplements - Nicotinamide and PyruvatePhase 2/3 · NCT05695027
- Aflibercept InjectionPhase 2 · NCT07891182
- Ahmed Tube SurgeryPhase 2 · NCT07891182
- Arm 1: TB0001 ophthalmic solution 0.9%Phase 2 · NCT07913074
- Arm 2: TB0001 ophthalmic solution 1.2%Phase 2 · NCT07913074
- G01 Eye Drops 100μg/mlPhase 2 · NCT07777861
- G01 Eye Drops 200μg/mlPhase 2 · NCT07777861
- Latanoprost 0.005% Ophthalmic SolutionPhase 2 · NCT06964191
- MetforminPhase 2 · NCT05426044
- NicotinamidePhase 2 · NCT07808333
- NT-501Phase 2 · NCT04577300
- NT-501 ECT implantPhase 2 · NCT02862938
- PA5108 Ocular Implant low dosePhase 2 · NCT06964191
- PA5108 Ocular Implant, high dosePhase 2 · NCT06964191
- TB0001 ophthalmic solution 1.5%Phase 2 · NCT07913074
- Timolol 0.05% eye dropsPhase 2 · NCT07913074
- AGN-193408 SRPhase 1/2 · NCT04499248
- ASP2767Phase 1/2 · NCT07770685
- Bimatoprost Implant System (High Dose)Phase 1/2 · NCT06120842
- Bimatoprost Implant System (Low Dose)Phase 1/2 · NCT06120842
- Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOLPhase 1/2 · NCT06120842
- EMLA 5% patchPhase 1/2 · NCT05694858
- EYED-002 (highest tolerated dose, 12-month)Phase 1/2 · NCT07619482
- EYED-002 High Dose (1442 U/mL topical insulin)Phase 1/2 · NCT07619482
- EYED-002 Low Dose (721 U/mL topical insulin)Phase 1/2 · NCT07619482
- GVB-2001-high dosePhase 1/2 · NCT06921317
- GVB-2001-low dosePhase 1/2 · NCT06921317
- Injector systemPhase 1/2 · NCT07036510
- Kinezodianone R hydrochloridePhase 1/2 · NCT05389267
- Lignocaine-loaded maltose microneedle array patchPhase 1/2 · NCT05694858
- Prophylactic Regimen APhase 1/2 · NCT07770685
- Prophylactic Regimen BPhase 1/2 · NCT07770685
- REGN22530Phase 1/2 · NCT07675824
- TimoD implantPhase 1/2 · NCT07036510
- Topical infliximabPhase 1/2 · NCT05180994
- Vehicle PlaceboPhase 1/2 · NCT07619482
- 16mg/ml KDR2-2 suspension eyedropPhase 1 · NCT04844619
- 4mg/ml KDR2-2 suspension eyedropPhase 1 · NCT04844619
- BIM-DRS High DosePhase 1 · NCT07641296
- BIM-DRS Low DosePhase 1 · NCT07641296
- ER-100 epigenetic therapyPhase 1 · NCT07290244
- eyeValvePhase 1 · NCT07480603
- Insulin, 20 unitsPhase 1 · NCT05206877
- insulin, 20 units three times dailyPhase 1 · NCT05206877
- insulin, 20 units twice dailyPhase 1 · NCT05206877
- Insulin, 4 unitsPhase 1 · NCT05206877
- insulin, 4 units three times dailyPhase 1 · NCT05206877
- insulin, 4 units twice dailyPhase 1 · NCT05206877
- PA5436 Ocular Implant, 115mcgPhase 1 · NCT06964061
- SpyGlass IOL with silicone pads (no drug)Phase 1 · NCT07641296
- Latanoprost (0.005%)Early phase 1 · NCT07425535
- occupational therapy interventions for low vision careEarly phase 1 · NCT06593405
- Yutiq 0.18 MG Drug ImplantEarly phase 1 · NCT04918121
Closest to patients
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.Amneal Pharmaceuticals, LLC (sponsor) · 9 hospitals in United StatesPhase 3Primary completion 2022
- Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle GlaucomaEfficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle GlaucomaAzienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino · Turin, Italy + 33 more hospitalsPhase 3Results expected 2026
- Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation SurgeryEffect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation SurgerySt. Joseph's Healthcare Hamilton (sponsor)Phase 3Results expected 2026
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Metformin as an Emerging Candidate for Diabetic Retinopathy, Agerelated Macular Degeneration and Glaucoma Pharmacotherapy: Evidence and Perspectives.
Metformin as an Emerging Candidate for Diabetic Retinopathy, Agerelated Macular Degeneration and Glaucoma Pharmacotherapy: Evidence and Perspectives.
Current reviews in clinical and experimental pharmacology
PubMed · PMID 42786857Publication
Ketogenic diet attenuates Müller cell activation and retinal neuroinflammation in autoimmune glaucoma through acetylation‑mediated FOXO signalling.
Ketogenic diet attenuates Müller cell activation and retinal neuroinflammation in autoimmune glaucoma through acetylation‑mediated FOXO signalling.
International journal of molecular medicine
PubMed · PMID 42757470Publication
Current role of cannabis in therapeutics: A critical perspective.
Current role of cannabis in therapeutics: A critical perspective.
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
PubMed · PMID 42697776Publication
An injectable hydrogel for localized sustained release of artesunate in postoperative fibrosis prevention after glaucoma filtration surgery.
An injectable hydrogel for localized sustained release of artesunate in postoperative fibrosis prevention after glaucoma filtration surgery.
Drug delivery
PubMed · PMID 42695923
Find fellow researchers
Groups with active Glaucoma work.
University of Miami
Coral Gables, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Massachusetts Eye and Ear Infirmary
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
University of California San Diego
San Diego, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Singapore Eye Research Institute
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Singapore National Eye Center
Singapore, Singapore
Team details appear once the team leader joins.
Is this your team? Claim it
Sun Yat-sen University
Guangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
All India Institute of Medical Sciences
New Delhi, India
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it